Ubiquitylation of RUNX3 by RNA-binding ubiquitin ligase MEX3C promotes tumorigenesis in lung adenocarcinoma

Table 1 Association between the mRNA Expression of MEX3C with clinical indicators

Clinical data	Patient number (n = 55)	MEX3C Expression		χ² value	P value
Clinical data	Patient number (n = 55)	High, n (%)	Low, n (%)	χ² value	P value
Sex
Male	33	16 (48.49)	17 (51.52)	0.7885	0.3746
Female	22	8 (36.37)	14 (63.63)	0.7885	0.3746
Age, year
≤ 60	21	11 (52.3)	13 (47.7)	0.0836	0.7725
> 60	34	13 (38.2)	18 (61.8)	0.0836	0.7725
Smoking history
Yes	36	16 (44.4)	20 (55.6)	0.0277	0.8678
No	19	8 (42.1)	11 57.9)	0.0277	0.8678
Histological types
LUSC	35	15 (42.9)	20 (57.1)	0.0236	0.8744
LUAD	20	9 (45)	11 (55)	0.0236	0.8744
Tumor size, cm
≤3	23	13 (56.6)	10 (43.4)	2.6686	0.1023
> 3	32	11 (34.4)	21 (65.6)	2.6686	0.1023
TNM stage
I–II	30	9 (30.0)	21 (70.0)	4.9899	0.0255^*
III–IV	25	15 (60.0)	10 (40.0)	4.9899	0.0255^*
LNM
Yes	23	12 (52.2)	11 (47.8)	1.1715	0.2791
No	32	12 (37.5)	20 (62.5)	1.1715	0.2791
Distant metastasis
Yes	33	18 (54.5)	15 (45.5)	3.9919	0.0457^*
No	22	6 (27.3)	16 (72.7)	3.9919	0.0457^*

55 patients with NSCLC were divided into high-expression (n = 24) and low-expression (n = 31) groups according to the mean value of MEX3C mRNA expression
Chi-square test or Fisher’s exact test was performed to evaluate the relationship between MEX3C expression and clinicopathological features of NSCLC
*P < 0.05

ISSN: 1479-5876